Shanghai Junshi Biosciences Co (HKSE:01877) Net Income From Continuing Operations : HK$-1,317.8 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Shanghai Junshi Biosciences Co's net income from continuing operations for the three months ended in Mar. 2024 was HK$-325.5 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1,317.8 Mil.

Shanghai Junshi Biosciences Co Net Income From Continuing Operations Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Net Income From Continuing Operations Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-849.17

-1,979.03

-725.68

-2,987.44

-2,723.39

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial														-728.52	-531.27	-461.04	-	-325.51

Shanghai Junshi Biosciences Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1,317.8 Mil.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Executives

Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Highbury Investment Pte Ltd	2101 Beneficial owner
Jovial Champion Investments Limited	2201 Interest of corporation controlled by you
Gong Ruilin	2202 Interest of your spouse
Vistra Trust (singapore) Pte. Limited	2201 Interest of corporation controlled by you
Lvc Holdings Limited	2201 Interest of corporation controlled by you
Lvc Management Holdings Limited	2201 Interest of corporation controlled by you
Lvc Innovate Limited	2201 Interest of corporation controlled by you
Lin Lijun	2307 Founder of a discretionary trust who can infl
Lvc Renaissance Fund Lp	2101 Beneficial owner
Lvc Renaissance Limited	2201 Interest of corporation controlled by you
Loyal Valley Innovation Capital (hk) Limited	2201 Interest of corporation controlled by you
Lv Di Kong Gu Ji Tuan Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines